Moreover, for specific types of cancer it may be possible to use new Mps1 inhibitors derived from the aforementioned chemotypes alone to replace the current chemotherapies or to be used in conjunction with other drugs and/or radiotherapy for the treatment of aggressive tumours of poor prognosis. Here, TTK is linked to neoplasm.